ACOR Archives - Market Exclusive

Home Tags ACOR

Acorda Therapeutics Inc (NASDAQ:ACOR) gets downgraded to Underweight by JPMorgan Chase...

ME Staff - October 24, 2019

Acorda Therapeutics Inc (NASDAQ:ACOR) gets downgraded to Neutral by HC Wainwright...

ME Staff - August 14, 2019

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Submission of Matters to...

ME Staff 8-k - June 20, 2019

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Departure of Directors or Certain...

ME Staff 8-k - March 8, 2019

Acorda Therapeutics Inc (NASDAQ:ACOR) had its Hold rating reiterated by Cantor...

ME Staff - February 15, 2019

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Departure of Directors or Certain...

ME Staff 8-k - January 28, 2019

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events

ME Staff 8-k - January 18, 2019

Acorda Therapeutics Inc (NASDAQ:ACOR) price target set to $18.00 by Oppenheimer

ME Staff - January 2, 2019

Acorda Therapeutics Inc (NASDAQ:ACOR) had its Neutral ➝ Hold rating reiterated...

ME Staff - December 26, 2018

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events

ME Staff 8-k - December 26, 2018

12 3...7 Page 1 of 7

/* */

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

September 18, 2023

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

September 11, 2023

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

August 21, 2023

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.

Tag: ACOR

Acorda Therapeutics Inc (NASDAQ:ACOR) gets downgraded to Underweight by JPMorgan Chase...

Acorda Therapeutics Inc (NASDAQ:ACOR) gets downgraded to Neutral by HC Wainwright...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Submission of Matters to...

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Departure of Directors or Certain...

Acorda Therapeutics Inc (NASDAQ:ACOR) had its Hold rating reiterated by Cantor...

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Departure of Directors or Certain...

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events

Acorda Therapeutics Inc (NASDAQ:ACOR) price target set to $18.00 by Oppenheimer

Acorda Therapeutics Inc (NASDAQ:ACOR) had its Neutral ➝ Hold rating reiterated...

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other Events

EDITOR PICKS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

POPULAR POSTS

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

POPULAR CATEGORY